BioCentury | Dec 30, 2020
Regulation

U.K. pairs green light for AZ-Oxford vaccine with aggressive distribution scheme to prioritize saving more lives

The U.K.’s emergency authorization of the COVID-19 vaccine from AstraZeneca and the University of Oxford prioritizes widespread vaccination with a flexible dosing schedule that’s supported by recent data showing up to 70% efficacy for a single...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Sep 11, 2020
Product Development

Loxo’s Bilenker on why reimbursement crisis is creating innovation, access crises: a BioCentury audio interview

COVID-19 has spotlighted the critical role of diagnostics and focused the world’s attention on the threats posed by infectious pathogens. Awareness is good, but what’s really needed to advance diagnostics...
BioCentury | Sep 7, 2020
Product Development

Merck’s Gerberding advocates for a head start on the next pandemic, beginning now: a BioCentury audio interview

First and foremost, the biopharma industry’s lesson from COVID-19 must be to advocate for the kinds of government engagement and investment that can provide a robust platform of countermeasures standing...
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds....
BioCentury | Jul 22, 2020
Product Development

Pharma survey: COVID-19 foreshadows a change in how business is done

As pharmas grapple with how to return to work, employees are being given the upper hand in deciding when and how to do so. The result could preface a transformation to a semi-virtual office structure,...
BioCentury | Jun 6, 2020
Product Development

Over 200 COVID-19 trials nearing completion should provide a busy summer of data readouts

Less than three months after COVID-19 reached pandemic status, and five since the virus was sequenced, drug development has reached the point where hundreds of clinical trials will soon read out. With a pile of...
BioCentury | May 23, 2020
Product Development

Making sense of the deluge of early COVID-19 vaccine data

It’s been a big couple of weeks for COVID-19 vaccine data, and the findings are simultaneously encouraging and disheartening. While they hint that some level of protection is achievable -- by multiple candidates -- more...
BioCentury | May 22, 2020
Product Development

Monkey rechallenge data provide COVID-19 neutralizing antibody benchmark for vaccine developers

As IMV and Vaxart prepare to advance their COVID-19 vaccine candidates into the clinic, monkey data from a Harvard-led team provide not only evidence of protective immunity following COVID-19 resolution, but also an antibody benchmark...
BioCentury | Apr 29, 2020
Product Development

India emerging as major COVID-19 vaccine manufacturer

At least six Indian companies are developing or co-developing COVID-19 vaccines, but India’s biggest contribution to fighting the pandemic is likely to come from its manufacturing might. The Serum Institute of India, the world’s largest...
Items per page:
1 - 10 of 592